FOx BIOSYSTEMS
- Industry
- Biotechnology
- Founded Year
- 2017
- Headquarters
- Diepenbeek, Belgium
- Employee Count
- 35
Key People
- Filip Delport - Co-Founder, Managing Director, and CEO
- Jeroen Lammertyn - Co-Founder
- Thomas Van Elzakker - CEO
- Joseph She - COO
- Kris Ver Donck - Vice President Marketing & Applications
- Nathalie Roosen - Board Member
- Bart Geers - Board Member
- Katleen Vandersmissen - President of the Board
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with backgrounds in MedTech and biotechnology.
The presence of multiple successful MedTech entrepreneurs in the leadership team suggests a strong foundation for strategic decision-making and innovation.
- Clinical Need
-
Aspect: Very Strong
Summary: The company's technology addresses a critical need for real-time, label-free biomolecular analysis in life sciences and biopharmaceutical research.
The demand for efficient and accurate biomolecular interaction analysis is high, and FOx BIOSYSTEMS' technology effectively fulfills this need.
- Competition
-
Aspect: Somewhat crowded
Summary: The market for biosensor technology is competitive, with several established players.
The presence of multiple competitors necessitates a strong value proposition and effective market penetration strategies.
- Technical Challenge
-
Aspect: Predictable
Summary: The development of fiber-optic-based SPR biosensors involves manageable technical challenges.
The technical challenges associated with the technology are well-understood and have been effectively addressed by the company.
- Patent
-
Aspect: Strong
Summary: The company holds patents related to its biosensor technology.
Strong patent protection enhances the company's market position and deters potential competitors.
- Financing
-
Aspect: Well-funded
Summary: The company has secured significant funding from reputable investors.
The 5.8 million raised in the B-round financing, along with support from investors like Heran Partners and the European Innovation Council, provides a solid financial foundation.
- Regulatory
-
Aspect: 510k/PMA
Summary: The company's products are subject to regulatory approvals.
Obtaining necessary regulatory approvals is a critical step for the commercialization of medical devices and biosensors.
Opportunity Rollup
- Odds of Success
- 3.7
- Peak Market Share
- 4.7
- Segment CAGR
- 7.5%
- Market Segment
- Biotechnology
- Market Sub Segment
- Biosensors
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.24 |
| 2 | 0.70 |
| 3 | 1.64 |
| 4 | 3.29 |
| 5 | 4.70 |
Key Takeaway
FOx BIOSYSTEMS, with its innovative biosensor technology and strong leadership, is well-positioned to capitalize on the growing demand for real-time biomolecular analysis in the biotechnology sector.